| abstract |
The present invention relates to compounds of the formula I in which substituents R<2> and R<3> are arranged in trans-configuration, Formula (I), wherein: R<1> is H or C1-C6 alkyl; C3-C7 cycloalkyl; R<2> is phenyl, optionally substituted with 1 to 5 substituents independently selected from the group comprising OH, C1-C6 -alkyl, halogen, nitro, cyano, SH, SR<4>, trihalo-C1-C6-alkyl, C1-C6 -alkoxy and phenyl, wherein R<4> is C1-C6 alkyl;R<3> is phenyl substituted with OR<5> wherein R<5> has the Formula (II), (III) or (IV) , wherein Y is chosen from NHR<4>, NR<4>2, NHCOR<4>, NHSO2R<4>, CONHR<4>, CONR<4>, CONR<4>2, COOH, COOR<4>, SO2R<4>, SOR<4>, SONHR<4>, SONR<4>2, a C3-C7 heterocyclic ring, saturated or unsaturated, containing one or two heteroatoms independently selected from the group consisting of O, S and N, optionally being substituted with 1 to 3 substituents independently selected from the group comprising H, OH, halogen, nitro, cyano, SH, SR<4>, trihalo-C1-C6- alkyl, C1-C6-alkyl and C1-C6 -alkoxy, preferably NHR<4>, NR2<4>, or a nitrogen heterocycle, wherein R<4> is as defined above, and the esters, ethers, and salts of the compounds of formula I, optionally along pharmaceutically acceptable excipients, a process for the preparation of the same, and a method of preventing and/or treating estrogen-related disease conditions in a subject using compounds of formula (I), or its salts, optionally along with pharmaceutically acceptable excipients. |